{"protocolSection": {"identificationModule": {"nctId": "NCT00448435", "orgStudyIdInfo": {"id": "110099"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma", "officialTitle": "A Study to Compare GW815SF HFA MDI With Concomitant Treatment With Salmeterol Xinafoate DPI Plus Fluticasone Propionate DPI and to Assess Long-term Safety of GW815SF HFA MDI"}, "statusModule": {"statusVerifiedDate": "2010-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-04"}, "primaryCompletionDateStruct": {"date": "2008-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-03-14", "studyFirstSubmitQcDate": "2007-03-15", "studyFirstPostDateStruct": {"date": "2007-03-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-01-19", "resultsFirstSubmitQcDate": "2009-06-25", "resultsFirstPostDateStruct": {"date": "2009-08-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2010-06-03", "lastUpdatePostDateStruct": {"date": "2010-06-08", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Study Director", "oldOrganization": "GSK"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "To evaluate the efficacy and safety of GW815SF HFA MDI 25/50\u00b5g 1 inhalation bid in comparison with concomitant treatment with salmeterol xinafoate DPI 25\u00b5g 1 inhalation bid plus fluticasone propionate DPI 50\u00b5g 1 inhalation bid in paediatric patients with asthma.\n\nTo evaluate the safety of long-term treatment of GW815SF HFA MDI 25/50\u00b5g 1 inhalation bid in paediatric patients with asthma."}, "conditionsModule": {"conditions": ["Bronchial Asthma"], "keywords": ["Salmeterol", "Fluticasone propionate", "Salmeterol/Fluticasone propionate combination", "Pediatric bronchial asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 51, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "SLM+FP First", "type": "ACTIVE_COMPARATOR", "description": "SLM(salmeterol) 25mcg + FP(fluticasone propionate) 50mcg twice daily in first intervention period and SFC(salmeterol/fluticasone propionate) 25/50mcg twice daily in second intervention period and (after washout period).", "interventionNames": ["Drug: GW815SF HFA MDI", "Drug: salmeterol and fluticasone propionate"]}, {"label": "SFC First", "type": "ACTIVE_COMPARATOR", "description": "SFC (Salmeterol/Fluticasone propionate combination) 25/50mcg twice daily in first intervention period and SLM (Salmeterol) 25mcg + FP (Fluticasone Propionate) 50mcg twice daily in second intervention period (after washout period).", "interventionNames": ["Drug: GW815SF HFA MDI", "Drug: salmeterol and fluticasone propionate"]}, {"label": "SFC", "type": "EXPERIMENTAL", "description": "SFC (salmeterol/fluticasone propionate combination) 25/50mcg twice daily in Extension period (after cross-over period).", "interventionNames": ["Drug: GW815SF HFA MDI"]}], "interventions": [{"type": "DRUG", "name": "GW815SF HFA MDI", "description": "salmeterol and fluticasone propionate combination", "armGroupLabels": ["SFC", "SFC First", "SLM+FP First"], "otherNames": ["salmeterol/fluticasone propionate combination"]}, {"type": "DRUG", "name": "salmeterol and fluticasone propionate", "description": "salmeterol + fluticasone propionate", "armGroupLabels": ["SFC First", "SLM+FP First"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods", "description": "Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \\[Weeks 1-4/Weeks 7-10\\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out (i.e., the last 7 days prior to the day of starting treatment period \\[Weeks 1-4/Weeks 7-10\\]).", "timeFrame": "Crossover Period Weeks 1-4, and 7-10"}], "secondaryOutcomes": [{"measure": "Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 4-week Treatment Periods", "description": "Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \\[Weeks 1-4/Weeks 7-10\\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.", "timeFrame": "Crossover Period Weeks 1-4, 7-10"}, {"measure": "Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 4-week Treatment Periods", "description": "Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \\[Weeks 1-4/Weeks 7-10\\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.", "timeFrame": "Crossover Period weeks 1-4, 7-10"}, {"measure": "Adjusted Mean Change From Baseline in Evening PEF During the 4-week Treatment Periods", "description": "Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \\[Weeks 1-4/Weeks 7-10\\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.", "timeFrame": "Crossover Period weeks 1-4, 7-10"}, {"measure": "Adjusted Mean Change From Baseline of Circadian Variation in Morning PEF(%) During the 4-week Treatment Periods", "description": "Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \\[Weeks 1-4/Weeks 7-10\\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.", "timeFrame": "Crossover Period Weeks 1-4, 7-10"}, {"measure": "Percentage of Subjects With Symptom-Free Nights & Days", "description": "Percentage of subjects with Symptom Free Nights \\& Days after 4 weeks of Treatment", "timeFrame": "Crossover Period Week 1-4, 7-10"}, {"measure": "Percentage of Subjects With Rescue Medication-Free Nights and Days", "description": "Percentage of subjects with Rescue Medication Free Nights \\& Days after 4 weeks of Treatment", "timeFrame": "Crossover Period Weeks 1-4, 7-10"}, {"measure": "Adjusted Mean Change From Baseline in Morning PEF During the 20-week Extension Treatment Period", "description": "Mean change from baseline = value at assessment period (mean of the values obtained at assessment period (Weeks 11-30).) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting of the Extension period (Weeks 11-30).", "timeFrame": "Extension Period Weeks 11-30"}, {"measure": "Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 20-Week Extension Treatment Period", "description": "Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \\[Weeks 11-30\\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).", "timeFrame": "Extension Period weeks 11-30"}, {"measure": "Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 20-week Extension Treatment Period", "description": "Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \\[Weeks 11-30\\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).", "timeFrame": "Extension Period weeks 11-30"}, {"measure": "Adjusted Mean Change From Baseline in Evening PEF During the 20-week Extension Treatment Period", "description": "Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \\[Weeks 11-30\\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).", "timeFrame": "Extension Period weeks 11-30"}, {"measure": "Adjusted Mean Change From Baseline of Circadian Variation in PEF(%) During the 20-Week Extension Treatment Period", "description": "Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \\[Weeks 11-30\\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).", "timeFrame": "Extension Period weeks 11-30"}, {"measure": "Percentage of Subjects With Symptom-Free Nights & Days After 20 Weeks of Treatment", "description": "Percentage of subjects with Symptom Free Nights \\& Days after 20 weeks of Treatment (at week 30).", "timeFrame": "Extension Period Weeks 11-30"}, {"measure": "Percentage of Subjects With Rescue Medication-Free Nights & Days After 20 Weeks of Treatment", "description": "Percentage of subjects with Rescue Medication Free Nights \\& Days after 20 weeks of Treatment (at week 30).", "timeFrame": "Extension Period Weeks 11-30"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n* Inclusion Criteria for Entry in Run-in Period\n\nA pediatric patient already diagnosed as having bronchial asthma who meets all of the following criteria is eligible for the study:\n\n* Male or female patients aged \u22655 and \u226414 years. Enrolment of a female patient of childbearing potential is allowed only if she is tested negative in the pregnancy testing at the start of Treatment Period 1 and if she agrees to undergo pregnancy testing at the protocol-specified timings and to take contraceptive measures without fail.\n* Written informed consent must be obtained from a legally acceptable representative of the subject. Consent of the subject him/herself should also be obtained, wherever possible, after giving an explanation in an as easy to understand as possible manner.\n* An outpatient who has been treated with ICS (FP 100\u03bcg/day or equivalent) for at least 4 weeks prior to Visit 1.\n* Able to use a peak flow meter in a correct manner in the investigator's/subinvestigator's judgment.\n* Able to use MDI and DPI in a correct manner (with the assistance of his/her caregiver as necessary) in the investigator's/subinvestigator's judgment.\n\nInclusion Criteria for Entry in Treatment Period 1 A subject will be randomized to one of the two treatment groups only if he/she has completed the run-in period and meets all the following criteria.\n\n1. Has a mean of morning PEF measurements in the last 7 days of the run-in period (excluding the first day of Treatment Period 1) \u226490% of his/her best PEF measurement .\n2. Was able to perform entry in the asthma diary and PEF measurements in a correct manner in the investigator's/subinvestigator's judgment.\n3. Able to use MDI and DPI in a correct manner (with the assistance of his/her caregiver as necessary) in the investigator's/subinvestigator's judgment.\n\nExclusion criteria:\n\n* Exclusion Criteria for Entry in Run-in Period\n\nA patient who applies any of the following criteria is not eligible for the study:\n\n* Admitted to the hospital due to asthma exacerbation within 8 weeks prior to Visit 1.\n* Used systemic steroid within 4 weeks prior to Visit 1.\n* Received antibacterials or antivirals for treatment of upper or lower respiratory tract infection within 2 weeks prior to Visit 1.\n* Has a safety problem in participation in the study because of a serious, uncontrolled systemic disease including nervous system disorder.\n* Has or is suspected to have deep-seated mycosis or infection to which no effective antibacterial agent is available.\n* Has or is suspected to have hypersensitivity to the investigational product, rescue medication or any ingredients of them.\n* Is pregnant or lactating, may be pregnant, or plans for pregnancy during the study period.\n* Has received the last dose in another clinical study within 2 months prior to this study.\n* Is not eligible for the study in the investigator's/subinvestigator's judgment.\n\nExclusion Criteria for Entry in Treatment Period 1\n\nEnrolment of a subject completing the run-in period into Treatment Period 1 will not be allowed if any of the following applies:\n\n1. Admitted to the hospital due to asthma exacerbation during the run-in period.\n2. Had upper or lower respiratory tract infection during the 2 weeks just before Visit 2.\n3. Used prohibited drugs during the 2 weeks just before Visit 2.\n4. Is not eligible for the study in the investigator's/subinvestigator's judgment.\n\nExclusion Criteria for Entry in Treatment Period 2\n\nEnrolment of a subject completing the washout period into Treatment Period 2 will not be allowed if any of the following applies:\n\n1. Admitted to the hospital due to asthma exacerbation during the washout period.\n2. Had upper or lower respiratory tract infection during the 2 weeks just before Visit 4.\n3. Used prohibited drugs during the 2 weeks just before Visit 4.\n4. Is not eligible for entry in Treatment Period 2 in the investigator's/subinvestigator's judgment.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "5 Years", "maximumAge": "14 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Chiba", "zip": "260-0001", "country": "Japan", "geoPoint": {"lat": 35.6, "lon": 140.11667}}, {"facility": "GSK Investigational Site", "city": "Kanagawa", "zip": "245-0018", "country": "Japan", "geoPoint": {"lat": 37.58333, "lon": 139.91667}}, {"facility": "GSK Investigational Site", "city": "Saitama", "zip": "360-0018", "country": "Japan", "geoPoint": {"lat": 35.90807, "lon": 139.65657}}, {"facility": "GSK Investigational Site", "city": "Saitama", "zip": "360-0812", "country": "Japan", "geoPoint": {"lat": 35.90807, "lon": 139.65657}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "154-0002", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "154-0017", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "158-0083", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "158-0097", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "SFC 50/100 Mcg/Day First", "description": "GW815SF (SFC; Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in first intervention period and SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in second intervention period (after washout period)."}, {"id": "FG001", "title": "SLM 50 Mcg + FP 100 Mcg/Day First", "description": "SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in first intervention period and GW815SF (SFC; Salmeterol/Fluticasone Propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in second intervention period (after washout period)."}], "periods": [{"title": "Treatment Period I - 4 Weeks", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "25"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "25"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Washout Period - 2 Weeks", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "25"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "25"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Treatment Period II - 4 Weeks", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "25"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "25"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Extension Period - 20 Weeks", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Overall Study Population", "description": "Randomized Population"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "51"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.3", "spread": "2.41"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "17"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "34"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Asian-Japanese Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "51"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Japan", "categories": [{"measurements": [{"groupId": "BG000", "value": "51"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods", "description": "Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \\[Weeks 1-4/Weeks 7-10\\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out (i.e., the last 7 days prior to the day of starting treatment period \\[Weeks 1-4/Weeks 7-10\\]).", "populationDescription": "PPS (Per Protocol Set): randomized subjects less those who did not complete treatment.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters/minute", "timeFrame": "Crossover Period Weeks 1-4, and 7-10", "groups": [{"id": "OG000", "title": "SFC 50/100 Mcg/Day", "description": "Per Protocol Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily"}, {"id": "OG001", "title": "SLM 50 Mcg + FP 100 Mcg/Day", "description": "Per Protocol Set who received SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg +FP (Fluticasone Propionate) DPI 50 mcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14.3", "spread": "4.53"}, {"groupId": "OG001", "value": "17.1", "spread": "4.53"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Difference between treatments \\[(SLM + FP)- SFC\\](SE) 2.8 (5.91)", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Equivalence margin + or - 15 L/min", "pValue": "0.6383", "pValueComment": "Confidence Interval", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "2.8", "ciPctValue": "95", "ciLowerLimit": "-9.10", "ciUpperLimit": "14.69", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "5.91"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 4-week Treatment Periods", "description": "Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \\[Weeks 1-4/Weeks 7-10\\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.", "populationDescription": "PPS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of predicted value", "timeFrame": "Crossover Period Weeks 1-4, 7-10", "groups": [{"id": "OG000", "title": "SFC 50/100 Mcg/Day", "description": "Per Protocol Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily"}, {"id": "OG001", "title": "SLM 50 Mcg + FP 100 Mcg/Day", "description": "Per Protocol Set who received SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg +FP (Fluticasone Propionate) DPI 50 mcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.38", "spread": "1.543"}, {"groupId": "OG001", "value": "6.73", "spread": "1.543"}]}]}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 4-week Treatment Periods", "description": "Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \\[Weeks 1-4/Weeks 7-10\\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.", "populationDescription": "PPS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of personal best value", "timeFrame": "Crossover Period weeks 1-4, 7-10", "groups": [{"id": "OG000", "title": "SFC 50/100 Mcg/Day", "description": "Per Protocol Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily"}, {"id": "OG001", "title": "SLM 50mcg + FP 100 Mcg/Day", "description": "Per Protocol Set who received SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.01", "spread": "1.480"}, {"groupId": "OG001", "value": "6.46", "spread": "1.480"}]}]}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Evening PEF During the 4-week Treatment Periods", "description": "Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \\[Weeks 1-4/Weeks 7-10\\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.", "populationDescription": "PPS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/min", "timeFrame": "Crossover Period weeks 1-4, 7-10", "groups": [{"id": "OG000", "title": "SFC 50/100 Mcg/Day", "description": "Per Protocol Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily"}, {"id": "OG001", "title": "SLM 50 Mcg + FP 100 Mcg/Day", "description": "Per Protocol Set who received SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg +FP (Fluticasone Propionate) DPI 50 mcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "16.3", "spread": "3.74"}, {"groupId": "OG001", "value": "15.8", "spread": "3.74"}]}]}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline of Circadian Variation in Morning PEF(%) During the 4-week Treatment Periods", "description": "Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period \\[Weeks 1-4/Weeks 7-10\\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.", "populationDescription": "PPS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of circadian variation", "timeFrame": "Crossover Period Weeks 1-4, 7-10", "groups": [{"id": "OG000", "title": "SFC 50/100 Mcg/Day", "description": "Per Protocol Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily"}, {"id": "OG001", "title": "SLM 50 Mcg + FP 100 Mcg/Day", "description": "Per Protocol Set who received SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg +FP (Fluticasone Propionate) DPI 50 mcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "spread": "0.638"}, {"groupId": "OG001", "value": "-0.08", "spread": "0.638"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Subjects With Symptom-Free Nights & Days", "description": "Percentage of subjects with Symptom Free Nights \\& Days after 4 weeks of Treatment", "populationDescription": "PPS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent of participants", "timeFrame": "Crossover Period Week 1-4, 7-10", "groups": [{"id": "OG000", "title": "SFC 50/100 Mcg/Day", "description": "Per Protocol Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily"}, {"id": "OG001", "title": "SLM 50 Mcg + FP 100 Mcg/Day", "description": "Per Protocol Set who received SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg +FP (Fluticasone Propionate) DPI 50 mcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "72.9"}, {"groupId": "OG001", "value": "81.3"}]}]}, {"title": "After 4 Weeks of Treatment", "categories": [{"measurements": [{"groupId": "OG000", "value": "91.7"}, {"groupId": "OG001", "value": "81.3"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Subjects With Rescue Medication-Free Nights and Days", "description": "Percentage of subjects with Rescue Medication Free Nights \\& Days after 4 weeks of Treatment", "populationDescription": "PPS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Crossover Period Weeks 1-4, 7-10", "groups": [{"id": "OG000", "title": "SFC 50/100 Mcg/Day", "description": "Per Protocol Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily"}, {"id": "OG001", "title": "SLM 50 Mcg + FP 100 Mcg/Day", "description": "Per Protocol Set who received SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg +FP (Fluticasone Propionate) DPI 50 mcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "87.5"}, {"groupId": "OG001", "value": "87.5"}]}]}, {"title": "After 4 Weeks of Treatment", "categories": [{"measurements": [{"groupId": "OG000", "value": "93.8"}, {"groupId": "OG001", "value": "87.5"}]}]}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Morning PEF During the 20-week Extension Treatment Period", "description": "Mean change from baseline = value at assessment period (mean of the values obtained at assessment period (Weeks 11-30).) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting of the Extension period (Weeks 11-30).", "populationDescription": "FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "Extension Period Weeks 11-30", "groups": [{"id": "OG000", "title": "SFC 50/100 Mcg/Day", "description": "Full Analysis Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "spread": "24.56"}]}]}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 20-Week Extension Treatment Period", "description": "Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \\[Weeks 11-30\\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).", "populationDescription": "FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of predicted value", "timeFrame": "Extension Period weeks 11-30", "groups": [{"id": "OG000", "title": "SFC 50/100 Mcg/Day", "description": "Full Analysis Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.46", "spread": "9.568"}]}]}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 20-week Extension Treatment Period", "description": "Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \\[Weeks 11-30\\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).", "populationDescription": "FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of personal best value", "timeFrame": "Extension Period weeks 11-30", "groups": [{"id": "OG000", "title": "SFC 50/100 Mcg/Day", "description": "Full Analysis Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.29", "spread": "8.541"}]}]}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Evening PEF During the 20-week Extension Treatment Period", "description": "Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \\[Weeks 11-30\\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).", "populationDescription": "FAS (Full Analysis Set) during the Exension period: all subjects switched to Extension period and received GW815SF HFA MDI.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/Min", "timeFrame": "Extension Period weeks 11-30", "groups": [{"id": "OG000", "title": "SFC 50/100 Mcg/Day", "description": "Full Analysis Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.7", "spread": "23.43"}]}]}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline of Circadian Variation in PEF(%) During the 20-Week Extension Treatment Period", "description": "Mean change from baseline = value at assessment period (mean of the values obtained at assessment period \\[Weeks 11-30\\]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).", "populationDescription": "FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of circadian variation", "timeFrame": "Extension Period weeks 11-30", "groups": [{"id": "OG000", "title": "SFC 50/100 Mcg/Day", "description": "Full Analysis Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.37", "spread": "3.568"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Subjects With Symptom-Free Nights & Days After 20 Weeks of Treatment", "description": "Percentage of subjects with Symptom Free Nights \\& Days after 20 weeks of Treatment (at week 30).", "populationDescription": "FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Extension Period Weeks 11-30", "groups": [{"id": "OG000", "title": "SFC 50/100 Mcg/Day", "description": "Full Analysis Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "84.0"}]}]}, {"title": "After 20 weeks of treatment (at week 30)", "categories": [{"measurements": [{"groupId": "OG000", "value": "84.8"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Subjects With Rescue Medication-Free Nights & Days After 20 Weeks of Treatment", "description": "Percentage of subjects with Rescue Medication Free Nights \\& Days after 20 weeks of Treatment (at week 30).", "populationDescription": "FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Extension Period Weeks 11-30", "groups": [{"id": "OG000", "title": "SFC 50/100 Mcg/Day", "description": "Full Analysis Set who received GW815SF (SFC, Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "90.0"}]}]}, {"title": "After 20 weeks of treatment (at week 30)", "categories": [{"measurements": [{"groupId": "OG000", "value": "89.1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "SFC 50/100 Mcg/Day", "description": "Safety Population who received GW815SF (SFC, Salmeterol/Fluticasone Propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in Crossover Period Weeks 1-4 and 7-10", "seriousNumAffected": 0, "seriousNumAtRisk": 51, "otherNumAffected": 12, "otherNumAtRisk": 51}, {"id": "EG001", "title": "SLM 50 + FP 100 Mcg/Day", "description": "Safety Population who received SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg +FP (Fluticasone Propionate) DPI 50 mcg twice daily in Crossover Period Weeks 1-4 and 7-10", "seriousNumAffected": 0, "seriousNumAtRisk": 50, "otherNumAffected": 10, "otherNumAtRisk": 50}, {"id": "EG002", "title": "SFC 50/100mcg/Day (Extension Period)", "description": "Safety Population who switched to Extension Period and received GW815SF HFA MDI 25/50mcg twice daily during the Extension period", "seriousNumAffected": 0, "seriousNumAtRisk": 51, "otherNumAffected": 35, "otherNumAtRisk": 51}], "otherEvents": [{"term": "Upper Respiratory Tract inflammation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 51}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 50}, {"groupId": "EG002", "numAffected": 17, "numAtRisk": 50}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 50}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 50}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 51}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 50}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 50}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 51}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 50}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 50}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 10", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 50}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 50}]}, {"term": "Stomatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 50}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 50}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit an investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not preceed the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Bronchial Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}, {"id": "D000068297", "term": "Fluticasone-Salmeterol Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000013566", "term": "Sympathomimetics"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Membrane", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Membrane", "relevance": "HIGH"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M249", "name": "Fluticasone-Salmeterol Drug Combination", "asFound": "0.13", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}